Co-Authors
This is a "connection" page, showing publications co-authored by Yi-Chun Lin and Chien-Yu Cheng.
Connection Strength
2.174
-
Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial. Infect Drug Resist. 2019; 12:937-945.
Score: 0.819
-
Multicenter evaluation of four immunoassays for the performance of early diagnosis of COVID-19 and assessment of antibody responses of patients with pneumonia in Taiwan. J Microbiol Immunol Infect. 2021 Oct; 54(5):816-829.
Score: 0.233
-
Clinical validation of an automated reverse transcription-insulated isothermal PCR assay for the detection of severe acute respiratory syndrome coronavirus 2. J Microbiol Immunol Infect. 2021 Jun; 54(3):522-526.
Score: 0.232
-
A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. Int J Infect Dis. 2020 Jul; 96:464-466.
Score: 0.221
-
Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. J Microbiol Immunol Infect. 2020 Jun; 53(3):488-492.
Score: 0.219
-
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 May 14; 12(1):3001.
Score: 0.059
-
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021 04 15; 12(1):2349.
Score: 0.059
-
Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathog. 2021 02; 17(2):e1009352.
Score: 0.058
-
A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). PLoS One. 2020; 15(12):e0242763.
Score: 0.057
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.057
-
Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nat Struct Mol Biol. 2020 10; 27(10):950-958.
Score: 0.056
-
Rapid establishment of a COVID-19 biobank in NHRI by National Biobank Consortium of Taiwan. Biomed J. 2020 08; 43(4):314-317.
Score: 0.055
-
Less Severe but Prolonged Course of Acute Hepatitis A in Human Immunodeficiency Virus (HIV)-Infected Patients Compared With HIV-Uninfected Patients During an Outbreak: A Multicenter Observational Study. Clin Infect Dis. 2018 10 30; 67(10):1595-1602.
Score: 0.050